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Abstract
Background: Critical illness increases the risk for poor mental health outcomes among both patients and their informal
caregivers, especially their surrogate decision-makers. Surrogates who must make life-and-death medical decisions on
behalf of incapacitated patients may experience additional distress. EMPOWER (Enhancing & Mobilizing the POtential for
Wellness & Emotional Resilience) is a novel cognitive-behavioral, acceptance-based intervention delivered in the intensive
care unit (ICU) setting to surrogate decision-makers designed to improve both patients’ quality of life and death and
dying as well as surrogates’ mental health.
Methods: Clinician stakeholder and surrogate participant feedback (n = 15), as well as results from an open trial (n =
10), will be used to refine the intervention, which will then be evaluated through a multisite randomized controlled
trial (RCT) (n = 60) to examine clinical superiority to usual care. Feasibility, tolerability, and acceptability of the
intervention will be evaluated through self-report assessments. Hierarchical linear modeling will be used to adjust for
clustering within interventionists to determine the effect of EMPOWER on surrogate differences in the primary
outcome, peritraumatic stress. Secondary outcomes will include symptoms of post-traumatic stress disorder, prolonged
grief disorder, and experiential avoidance. Exploratory outcomes will include symptoms of anxiety, depression, and
decision regret, all measured at 1 and 3 months from post-intervention assessment. Linear regression models will
examine the effects of assignment to EMPOWER versus the enhanced usual care group on patient quality of life or
quality of death and intensity of care the patient received during the indexed ICU stay assessed at the time of the
post-intervention assessment. Participant exit interviews will be conducted at the 3-month assessment time point and
will be analyzed using qualitative thematic data analysis methods.
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Discussion: The EMPOWER study is unique in its application of evidence-based psychotherapy targeting peritraumatic
stress to improve patient and caregiver outcomes in the setting of critical illness. The experimental intervention will be
strengthened through the input of a variety of ICU stakeholders, including behavioral health clinicians, physicians,
bereaved informal caregivers, and open trial participants. Results of the RCT will be submitted for publication in a peer-
reviewed journal and serve as preliminary data for a larger, multisite RCT grant application.
Trial registration: ClinicalTrials.gov, NCT03276559. Retrospectively registered on 8 September 2017.
Keywords: Critical illness, Psychological distress, Peritraumatic distress, Medical decision-making, Communication,
Surrogate decision-makers, Caregivers
Background
Critical illness increases the risk for poor mental health
outcomes among both patients [1] and families [2]. The
burden of psychological distress may be especially great
for the surrogate decision-makers of intensive care unit
(ICU) patients who are unable to adequately communi-
cate their treatment decisions due to factors including
altered consciousness, requirement for invasive life sup-
port, or the severity of their underlying illness. This
leaves surrogate decision-makers in the challenging situ-
ation of potentially needing to make life-and-death deci-
sions without the patient’s input about treatment
preferences at a time while they themselves are signifi-
cantly distressed. Given that ICU surrogates are at
heightened risk for poor psychological outcomes [3, 4],
there have been calls for interventions that can help ICU
surrogates cope throughout the illness course, from ICU
admission through discharge or bereavement, in order
to improve surrogate mental health [5].
Past efforts to address these challenges have so far
produced disappointing results for improving end-of-
life (EoL) care and surrogate mental health; moreover,
some psychosocial interventions may carry risk. In a
recent randomized controlled trial (RCT), post-
traumatic stress disorder (PTSD) symptoms increased
for surrogate decision-makers of ICU patients who re-
ceived a family meeting intervention led by palliative
care medical specialists that was designed to reduce
surrogate anxiety and depression [6]. Another inter-
vention designed to improve mental health outcomes
through sending handwritten condolence cards to rel-
atives of patients who died in the ICU was shown to
worsen depression and PTSD symptoms [7]. A web-
based, personalized decision aid for surrogates of ICU
patients did not reduce surrogates’ symptoms of de-
pression, anxiety, or PTSD or change clinical out-
comes compared to usual care [8]. Finally, a
multicomponent, nurse-led intervention designed to
reduce depression, anxiety, and PTSD focused on the
provision of emotional, communication, decisional,
and anticipatory grief support for ICU family
caregivers, but did not utilize targeted strategies to
reduce clinical symptoms [9, 10]. In fact, the investi-
gative team specifically noted that the interventionists
did not have advanced training in patient counseling
[9], and, similar to other trials, the results showed no
significant effects on the primary mental health out-
comes of anxiety or depression, or on secondary out-
comes of PTSD [11].
The primary limitation of these interventions is that
although they targeted longer-term (e.g., 3 and 6 months
post intervention) mental health outcomes, they were
not explicitly designed using empirically supported psy-
chological treatments to address clinically significant
mental health symptoms or to provide coping skills that
could be applied beyond the ICU stay. Furthermore, they
were not delivered by trained mental health clinicians.
In fact, White et al. [5] concluded in response to the
study findings that a brief, “psychologically focused
intervention” should be developed and tested.
To address these limitations, we propose to target
surrogate decision-maker mental health as a way to
both improve surrogates’ capacity to cope with the
stress of the patient’s ICU stay and also improve
decision-making on the patient’s behalf. We propose
to develop, refine, and evaluate EMPOWER (Enhan-
cing & Mobilizing the POtential for Wellness & Emo-
tional Resilience), a very brief mental health
intervention for surrogate decision-makers of ICU pa-
tients who are unable to communicate their EoL care
preferences. Delivered by a trained mental health pro-
fessional in the ICU setting, EMPOWER is theoretic-
ally grounded in cognitive-behavioral and acceptance-
based therapies. EMPOWER aims to improve surro-
gate mental health outcomes, increase rates of advance
care planning (e.g., rates of Do Not Resuscitate (DNR)
orders or advanced directive completion), promote
value-concordant care through clarifying surrogate
perceptions of incapacitated patients’ treatment pref-
erences, improve patient quality of life/death as per-
ceived by the surrogate, and reduce surrogate
decisional regret about the patient’s ICU care.
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Methods
Overview
The methods for the EMPOWER study were developed
in accordance with the SPIRIT guidelines [12] (Add-
itional file 1). Any prospective amendments to the
protocol, eligibility, or outcomes will first be approved
by the institutional review boards of the study sites.
Key study objectives
1. Develop EMPOWER for surrogate decision-makers
of critically ill ICU patients who are unable to make
medical decisions. Key informants, including be-
reaved informal caregivers of ICU patients and cli-
nicians, will be asked to evaluate the EMPOWER
intervention manual to increase its potential toler-
ability, acceptability, and efficacy.
2. Determine the feasibility, tolerability, acceptability,
and preliminary effects of EMPOWER on surrogate
mental health. We hypothesize that the revised
EMPOWER intervention will be feasible, tolerable,
and acceptable. The primary outcome will be
symptoms of peritraumatic distress measured
following the intervention compared to enhanced
usual care. Additional outcomes at 1-month and 3-
month follow-up from post-intervention assessment
will be compared to enhanced usual care as well.
3. Estimate the effects of EMPOWER on patient
outcomes in the months following the post-
intervention assessment. Patients who receive EM-
POWER are hypothesized to have higher rates of
engagement in advance care planning (e.g., a DNR
order completed), better surrogate-reported quality
of life/quality of death, and more value-concordant
care (measured by comparing intensity of care at
EoL to surrogate perception of patient treatment
preferences) compared to patients whose surrogates
receive enhanced usual care.
Trial design
The EMPOWER study is comprised of two phases con-
ducted simultaneously in preparation for the subsequent
RCT. A timeline of the EMPOWER project is presented
in Fig. 1. Phase 1 will first involve both an open trial, en-
rolling 10 surrogate decision-makers who will receive
the EMPOWER intervention, and provide feedback
about administration of EMPOWER. The concurrent
manual refinement activities will involve obtaining feed-
back on the EMPOWER intervention manual itself from
15 stakeholders (bereaved informal caregivers and ICU
clinicians or mental health clinicians). Feedback from
both the open trial and stakeholder interviews will then
be used to refine the EMPOWER intervention.
Phase 2 will involve a multicenter, open-label, parallel-
group, exploratory RCT, which aims to enroll up to 60
eligible surrogates of 60 incapacitated patients in the
ICU. This sample size ensures stable estimates of treat-
ment effects and confidence intervals, and, in case the
effects of EMPOWER happen to be large, adequate (~
80%) statistical power to detect a minimum treatment
effect size (Cohen’s d) of 0.75 (at α = 0.05). Surrogates
will be block-randomized to either the EMPOWER
intervention or enhanced usual care and will complete
self-report measures (n = 30 in each group). A usual care
comparator will be enhanced with a packet providing
general information and recommendations on serving as
an informal caregiver from the National Alliance for
Caregiving (http://www.caregiving.org/pdf/resources/
CFC.pdf) as well a handout documenting site-specific
resources for caregivers at each hospital. We will docu-
ment the availability and use of social support services
provided within each of the three participating ICU sites
to control for inter-institutional variability on the
provision of supportive services as usual care.
Location and participants
The study will take place at NewYork-Presbyterian
Hospital/Weill Cornell Medical Center, NewYork-
Presbyterian Queens, and Memorial Sloan Kettering
Cancer Center in New York City. Research assistants
will screen potential patient and informal caregiver
dyads, and consent them as research participants fol-
lowing approval from ICU physicians and guidance
from allied health staff. This study will involve ICU
clinicians, patients, and patients’ surrogates as partici-
pants as well as stakeholders. Feedback from patients
and informal caregivers is integrated into several
stages of the EMPOWER trial. Bereaved informal
caregivers of ICU patients and ICU clinicians will be
consulted to improve the EMPOWER intervention.
Additionally, participants in the open trial will be
consulted through exit interviews to share their sug-
gestions in improving the intervention, assessments,
and recruitment procedures of the trial. All research
participants will be compensated to promote retention
and complete follow-up. Participating stakeholders
will receive compensation of a $50 gift card after
reviewing the manual and providing feedback. Partici-
pating surrogates in the open trial and RCT will re-
ceive $25 following completion of each assessment
and exit interview.
Eligibility criteria
Inclusion criteria for open trial and RCT participants:
1. Patients (age > 21 years) in the ICU/step-down
units who cannot communicate treatment
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preferences, as determined by ICU physicians or
fellows, and whose ICU physicians or fellows would
not be surprised if the patient did not survive more
than 3 months.
2. Informal caregivers of ICU patients whom ICU
physicians or fellows indicate as the decision-
making surrogate for the patient, or who is listed as
such in the patient’s medical record.
3. Surrogates must speak English.
4. Surrogates must either meet the threshold for a
high degree of dependence on the patient
(determined by the summed score of the overall
dependence and emotional dependence on the
patient items of the Partner Dependency Scale [13]
as greater than 8) or a high degree of anxiety
(determined by scoring greater than 5 on either
anxiety item from the McGill Quality of Life
Questionnaire [14]).
Exclusion criteria for open trial and RCT participants:
1. Patients and surrogates who do not meet the
eligibility criteria or surrogates who endorse
suicidal ideation in the past month based on
responses to the Columbia Suicide Severity
Rating Scale [15].
Inclusion criteria for stakeholders:
Open Trial Phase
10 eligible surrogates of 10 incapacitated ICU 
patients will participate in the EMPOWER 
open trial (no randomization; no control arm).
Manual Refinement Phase
Up to 15 qualified stakeholders (bereaved 
caregivers of ICU patients identified by ICU 
physicians and clinicians with expertise in ICU 
or mental health care) will be interviewed after 
reviewing the EMPOWER intervention manual.   
Feedback from open trial and stakeholder interviews will be used to refine EMPOWER.
Pilot Randomized Controlled Trial Phase  
60 eligible dyads of surrogates and 
incapacitated patients in the ICU will be invited 
to participate. Surrogates will be randomized 
into one of two groups. 
EMPOWER Condition 
(n = 30 surrogates; 50%) 
T1 = Pre-intervention/Baseline 
T2 = Post-intervention 
(Within 1 week of completion of intervention) 
Booster Call 1 
(~2 weeks after intervention in the ICU) 
Booster Call 2 
(~2 weeks after Booster Call 1) 
Receive EMPOWER in the ICU 
T3 = First Follow-up Assessment 
 (1 month post T2) 
T4 = Second Follow-up Assessment & Exit 
Interview (3 months post T2) 
Enhanced Usual Care (no EMPOWER) 
(n = 30 surrogates; 50%) 
T1 = Pre-intervention/Baseline 
T2 = Post-intervention 
(Within 1 week of provision of resources) 
Receive informal caregiver resources  
T3 = First Follow-up Assessment 
 (1 month post T2) 
T4 = Second Follow-up Assessment  
(3 months post T2) 
The revised EMPOWER manual will be sent to 
stakeholders for a second round of feedback. 
Fig. 1 EMPOWER timeline. EMPOWER Enhancing & Mobilizing the POTential for Wellness & Emotional Resilience among Surrogate Decision-
Makers of ICU Patients, ICU intensive care unit
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1. Bereaved family caregivers of patients treated in the
ICU identified by referring clinicians and through
support groups, clinics, and word of mouth.
2. Clinicians with expertise in mental health care and/
or critical care including, but not limited to, nurses,
nurse practitioners, social workers, psychologists,
hospital chaplains, psychiatrists, and other
physicians.
Exclusion criteria for stakeholders:
1. Bereaved informal caregivers or clinicians who do
not meet the eligibility criteria.
Interventions
The EMPOWER intervention will be administered by
trained mental health professionals such as psycholo-
gists or social workers. The EMPOWER intervention
targets symptoms of peritraumatic stress and anticipa-
tory grief that may interfere with optimal decision-
making on the patient’s behalf or lead to adverse health
outcomes such as prolonged grief disorder or PTSD
following the patient’s death or discharge from the ICU.
The EMPOWER intervention seeks to act on these
symptoms through the reduction of “experiential avoid-
ance” [16, 17] and teaching of coping skills, empirically
supported techniques from cognitive-behavioral therapy
[18–20], and acceptance and commitment therapy [21–
23] that can be applied during the ICU stay and in the
immediate aftermath of the ICU stay. It consists of six
discrete modules that take approximately 15–20 min
each to complete (for an approximate total of 1.5–2 h)
and can be delivered flexibly to accommodate the nu-
merous interruptions and unexpected crises typical in
an ICU setting. The EMPOWER modules include em-
pathetic listening and alliance building, breathing
retraining, grounding exercises, guided mindfulness
meditation, psychoeducation about cognitive-behavioral
and acceptance-based coping strategies, invoking of the
patient’s voice through an imaginal dialogue, and
coping rehearsal to prepare for potentially distressing
scenarios. A brief summary of the structure of the
intervention is presented in Table 1. The six modules
can be delivered in the ICU in a single session or in
multiple brief sessions based on the surrogate’s prefer-
ence. Following the initial EMPOWER session con-
ducted in the ICU, two booster sessions will be
delivered by phone 2 and 4 weeks after the end of the
intervention. Booster sessions will focus on issues rele-
vant to the surrogate, such as bereavement, and review-
ing the skills taught in the original session to coping
with new challenges. Each booster session will last ap-
proximately 45–60 min. Of note, the content and for-
mat of EMPOWER will be further developed through
the input of surrogates in the open trial, bereaved infor-
mal caregivers who have had relevant experiences in
the ICU, and clinicians with expertise in mental health
and/or critical care.
EMPOWER will be delivered by at least a master’s-
level mental health clinician interventionist who will re-
ceive intensive training prior to delivering the interven-
tion and regular supervision after each session. The
interventionists will communicate with the medical team
as needed, but will provide a safe space separate from
the ICU clinicians without any agenda about the pa-
tient’s care. While a multidisciplinary approach in the
ICU is invaluable, anecdotal evidence suggests that inter-
personal dynamics between the surrogates and the med-
ical team sometimes complicate surrogates’ ability to
independently consider their and the patient’s wishes
(e.g., surrogates have reported feeling pressured by hos-
pital staff to sign a DNR order while the patient is in the
ICU, and they feel conflicted and/or defensive about this
request). Sessions will be audio recorded (or video re-
corded if the surrogate provides permission) so that
treatment fidelity can be regularly monitored and inde-
pendently rated by trained research assistants. We will
monitor the progress of all participants and request
their continued participation in the EMPOWER inter-
vention. If a participant has not completed part of
Table 1 The EMPOWER intervention
EMPOWER Enhancing & Mobilizing the POtential for Wellness & Emotional Resilience, ICU intensive care unit
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the intervention, we will contact that participant to
remind and encourage them to continue up to three
times, with an upper limit of contact in place to pre-
vent bothering participants.
Enhanced usual care will consist of the various interac-
tions a surrogate may have with clinicians in the ICU,
which may include social work and chaplaincy staff who
serve as providers of psychosocial support. Additionally,
a packet providing information about informal caregiv-
ing and resources will be provided to surrogates in the
control group by research staff. Lastly, a referral list of
site-specific resources such as caregiver support groups
and hotlines will be provided. Use of the various compo-
nents of enhanced usual care will be monitored and ex-
tensively tracked through review of notes in the patient’s
medical record and surrogate self-report. Enhanced
usual care was chosen as the comparator in this study in
order to determine whether the EMPOWER interven-
tion serves as an effective support for surrogates above
and beyond standard practice. Having three sites, each
with unique practices for supporting informal caregivers
and surrogates, will allow the intervention to be com-
pared to multiple smaller subsets of standard treatment,
and at the same time also reflect general psychosocial in-
formal caregiver support.
Surrogate decision-makers will be permitted to con-
tinue to see any outside mental health professionals dur-
ing the trial. Mental health treatment they receive from
outside professionals, as reported to study clinicians by
the subjects, will be documented and controlled for dur-
ing data analysis.
Assignment of interventions
Participants in the open trial will all be assigned to the
EMPOWER intervention. Participants in the RCT will
be randomized to either EMPOWER or the control
group with a block randomization procedure in REDCap
[24] using computer-generated random numbers gener-
ated in R Studio [25]. Research assistants will randomize
a participant using REDCap following the participant’s
completion of the consent, eligibility screener, and base-
line assessment. Because a co-principal investigator will
be conducting supervision for the interventionists, and
because different assessments will be administered de-
pending on the intervention assignment, the only person
completely blinded to group assignment will be the data
analyst/statistician.
Outcomes
1. The first goal of this study is to determine the
feasibility and acceptability of the EMPOWER
intervention. These outcomes will be measured
quantitatively within the week following the
intervention (T2) through a post-intervention ques-
tionnaire and at 1-month (T3) and 3-month (T4)
follow-up from post-intervention assessment (in-
cluding a qualitative exit interview at T4 of study
participants who were assigned to the EMPOWER
intervention arm). More specifically, these assess-
ments will measure participant-perceived helpful-
ness/satisfaction to determine acceptability.
Tolerability will be measured in these assessments
through participant reports of negative experiences,
emotional difficulties, and perceived costs and bene-
fits of participating in the intervention.
Targets will include completion of 4/6 modules for
feasibility, and for acceptability an average response
score of at least 4 to items 1, 3, and 7 of the post-
intervention satisfaction questionnaire among at
least 60% of intervention recipients. Rates of re-
cruitment, reasons for refusal, number of modules/
booster calls completed, and study attrition will also
be examined. Drop-out post intervention will not
be considered a metric of tolerability due to the
highly stressful and variable circumstances (e.g., be-
reavement) of ICU caregiving, unless participants
drop out of the study and specifically express that
they consider it to be too distressing.
2. The EMPOWER study also aims to improve
surrogates’ symptoms of psychological distress. This
will be measured by comparing the EMPOWER
group to the enhanced usual care group at multiple
time points. The primary outcome will be in
peritraumatic distress at post-intervention assess-
ment (T2), administered within a week of the inter-
vention. Secondary outcomes will be differences in
symptoms of PTSD, prolonged grief disorder, and
experiential avoidance, and exploratory outcomes
will be anxiety, depression, and decisional regret at
1-month and 3-month follow-up from post-
intervention assessment (T3 and T4).
3. Additionally, the EMPOWER study aims to
improve patient outcomes through promoting
value-concordant care, quality of life, and quality of
death. Rates of value-concordant care will be mea-
sured through comparing surrogate perceptions of
patient treatment preferences assessed at baseline
(e.g., a preference to prioritize care focused on qual-
ity of life over quantity of life) with the intensity of
care provided in the indexed ICU stay (e.g., indica-
tion of cardiopulmonary resuscitation, dialysis,
mechanical ventilation, chemotherapy, or parenteral
nutrition, and palliative care in the medical record).
We will compare surrogate-assessed patient quality
of death (for patients who died) using the CEQUEL
[26] between groups, measured at either T3 or T4,
depending on which time point first follows the
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patient’s death. Surrogate-assessed patient quality of
life will be assessed as relevant to the most recent
week (or week alive) through Likert-type items pre-
viously published [27], as well as through a revised
version of the CEQUEL, and will be measured at 1-
month follow up (T3), 3-month follow up (T4),
both, or neither, depending on patient status.
Measures
Demographics
Surrogate decision-makers will be asked in a baseline as-
sessment, occurring either in the clinic or over the tele-
phone, their own and the patient’s age (years), gender, race,
education, mental health history, income, marital status, re-
ligious/spiritual beliefs, advance care planning knowledge/
understanding, treatment preferences, and prognostic un-
derstanding and their relationship with the patient. Stake-
holders will report on their own demographics.
Medical factors for patients
We will abstract the medical chart to record patients’ pri-
mary hospital and ICU admitting diagnoses (e.g., stage IV
pancreatic or NSCL cancer), Do Not Resuscitate/Do Not
Intubate order status, advance care planning items (e.g.,
Living Will, Health Care Proxy, Health Care Power of At-
torney), palliative care consultations, and care plans ob-
tained from the medical chart or ICU physicians and
fellows. This information will be compiled as a medical
chart abstraction and matched with surrogate-assessed pa-
tient treatment preferences assessed at baseline to create a
measure of rates of value-concordant care. These medical
factors, in addition to the CEQUEL [26], will serve to
measure the outcomes specified in Objective #3 (see Data
analysis plan).
Psychosocial factors for surrogate decision-makers
A description of each quantitative measure used at each
assessment is provided in Table 2, and a timeline of as-
sessments is provided in Fig. 2.
Screener
The screener consists of four items from the McGill
Quality of Life Questionnaire [14], two items from the
Partner Dependency Scale [13], and three items from
the Columbia Suicide Severity Rating Scale [15]. We will
also obtain the surrogate’s physician/healthcare provider
information at baseline should a medical or mental
health emergency arise.
Pre-intervention/baseline assessment (T1)
Psychiatric history, demographics, and treatment prefer-
ences; Prolonged Grief Disorder (PG-12) Caregiver Ver-
sion [28–30]; Fears of Losing Loved Ones Scale
(FOLLOS); Peritraumatic Distress Inventory (PDI) [31];
Peritraumatic Dissociative Experiences Questionnaire
(PDEQ) [32]; Impact of Events Scale—Revised (IES-R)
[33]; Brief Experiential Avoidance Questionnaire (BEAQ)
[34]; State Trait Anxiety Questionnaire—Trait Scale
(STAI-Y Trait) [35]; Patient Health Questionnaire
(PHQ-9) [36]; Distress Tolerance Scale (DTS) [37] re-
vised version; Caregiver Self-Efficacy in the ICU Scale;
and Decision Regret Scale (DRS)—EMPOWER [38].
Post-intervention assessment (T2) administered within 1
week of intervention
PG-12 (if patient is alive); FOLLOS (if patient is alive);
PG-13 (if patient is deceased) [28–30]; PDI; PDEQ; IES-
R; BEAQ; STAI-Y Trait; DTS revised version; Caregiver
Self-Efficacy in the ICU Scale; DRS—EMPOWER; and
Post-Intervention Satisfaction Questionnaire (PISQ).
One-month follow-up from post-intervention assessment
(T3)
PG-12 (if patient is alive); FOLLOS (if patient is alive);
PG-13 (if patient is deceased); PDI; IES-R; BEAQ; STAI-
Y Trait; DTS revised version; CEQUEL-R (if patient is
alive) [26]; CEQUEL [26] (if patient is deceased); quality
of life (if patient is alive) [39]; quality of death (if patient
is deceased) [39]; DRS—EMPOWER; and medical infor-
mation update.
Three-month follow-up from post-intervention assessment
(T4)
PG-12 (if patient is alive); FOLLOS (if patient is alive);
PG-13 (if patient is deceased); PDI; IES-R; BEAQ; STAI-Y
Trait; PHQ-9; DTS revised version; Critical Care Family
Satisfaction Survey— EMPOWER; CEQUEL-R (if patient
is alive); CEQUEL (if patient is now deceased, but was
alive at T3); quality of life (if patient is alive); quality of
death (if patient is deceased); DRS—EMPOWER; medical
information update; and qualitative exit interview (for pa-
tients receiving the EMPOWER intervention only).
Qualitative data
Surrogates will provide feedback on the intervention in a
post-intervention satisfaction questionnaire at T2 and a
one-on-one semi-structured exit interview at T4 con-
ducted over the phone or in person solely for participants
assigned to the experimental arm. Stakeholders will pro-
vide feedback on the intervention manual in self-report
questionnaires, written form, and/or in-person interviews.
If participants drop out of the study, the investigative
team will attempt to ask them for their reasons for ceas-
ing to participate, but no further data will be collected.
Data analysis plan
The following are descriptions of the statistical proce-
dures performed to test each of the hypotheses.
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Table 2 List of assessments
CSSRS Columbia Suicide Severity Rating Scale, EMPOWER Enhancing & Mobilizing the POtential for Wellness & Emotional Resilience, ICU intensive care unit, PTSD
post-traumatic stress disorder, T1 pre-intervention/baseline assessment, T2 post-intervention assessment administered within 1 week of intervention, T3 1-month
follow-up from post-intervention assessment, T4 3-month follow-up from post-intervention assessment
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Participant data will be stored in a locked file cabinet
and using a secured REDCap database. Missing data will
be estimated using a multiple imputation procedure de-
scribed by Schafer and Olsen [40]. There will not be a
data monitoring committee due to the trial’s relatively
short duration and the minimal risks that the inter-
vention poses. Trial data will not be independently
audited. An interim analysis of the pilot data will
occur to inform the conduct of the RCT and edits to
the EMPOWER manual.
Objective #1: refine EMPOWER for surrogate decision-
makers of critically ill patients who are unable to
communicate in the ICU
We will use thematic content analysis, a well-established,
systematic qualitative analysis approach in health research,
SPIRIT Figure for Randomized Controlled Trial Portion of EMPOWER Trial 
tuo-esolCtnemssessAtnemllornE
TIMEPOINT -T1 Baseline(T1)
Following 
Completion 
of Baseline 
Assessment
Within One 
Week of 
Completion 
of
Intervention
(T2)
One Month 
from T2 (T3) 
Three 
Months 
from T2 (T4)
Chart
Review 
 SURROGATE ENROLLMENT: 
Eligibility screen X       
Informed consent X       
Allocation   X     
 PHYSICIAN ENROLLMENT: 
Eligibility screen    X    
Informed consent    X    
INTERVENTIONS: 
EMPOWER 
Enhanced Usual Carea
ASSESSMENTS:
Demographics  X      
PG-12/13  X  X Xs Xs
Fears of Losing Loved Ones Scale  X  X X X 
STAI  X  X X X  
PHQ-9  X   X X  
BEAQ  X  X Xs Xs
IES-R  X  X Xs Xs
Distress Tolerance Scale  X  X X X  
PDI  Xp  Xp X X  
Decision Regret Scale  X  X X X  
Decision Regret Distress 
Thermometer  X  X X X  
PDEQ  X  X    
Caregiver Self-Efficacy in the ICU 
Scale  X  X    
EMPOWER/EUC Satisfaction 
Questionnaire    X    
Physician Questionnaire    X    
CEQUEL/CEQUEL-R     X X  
Quality of Life/Quality of Death     X X  
Critical Care Family Satisfaction 
Survey     X   
Medical Information Update     X X  
Exit Interviewb      X  
Medical Chart Review       X 
a  Exposure dependent on patient length of stay 
b For participants assigned EMPOWER only
p Primary outcome 
s Secondary outcomes 
Fig. 2 Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) figure. BEAQ Brief Experiential Avoidance Questionnaire,
CEQUEL caregiver evaluation of the quality of end-of-life care, EMPOWER Enhancing & Mobilizing the POtential for Wellness & Emotional
Resilience, EUC, ICU intensive care unit, IES-R Impact of Events Scale—Revised, PDEQ Peritraumatic Dissociative Experiences Questionnaire, PDI
Peritraumatic Distress Inventory, PG-12/13 Prolonged Grief Disorder-12/13, PHQ-9 Patient Health Questionnaire, STAI State Trait
Anxiety Questionnaire
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to identify themes from stakeholder participants’ narratives
and exit interviews. We will follow Morse’s guidelines for
conducting rigorous qualitative research (e.g., audit trail,
saturation) [41–46] using Atlas.ti software. We will inde-
pendently review each interview transcript as well as quali-
tative data gathered from manual edits and Delphi survey
responses, and will synthesize and interpret participants’
feedback about the content of the EMPOWER manual.
Objective #2: determine the feasibility, acceptability,
tolerability, and preliminary effects of EMPOWER on
surrogate mental health
We will compute descriptive statistics to characterize
the feasibility and acceptability of EMPOWER by exam-
ining helpfulness/satisfaction ratings, rates of recruit-
ment, reasons for refusal, and number of modules/
booster calls completed. These will be used to determine
whether the EMPOWER intervention meets the targets
detailed earlier in the outcomes. Qualitative data analysis
will be used to analyze data from open-ended questions
to identify the most helpful components of EMPOWER.
To evaluate the preliminary effects of EMPOWER on
peritraumatic stress at post-intervention assessment (T2)
in the RCT, we will use a hierarchical linear modeling
(HLM) and an intent-to-treat approach. HLM is statisti-
cally appropriate because it corrects for clustering within
interventionists and within surrogates by modeling them
as random effects. This will also provide a treatment as-
signment model coefficient and effect size estimate for
our future, larger study.
HLM modeling will determine differences between
surrogates and patients assigned to EMPOWER vs en-
hanced usual care to examine the primary, secondary,
and exploratory outcomes described earlier. HLM
models will include covariates, either as fixed effect or
time varying (e.g., patient death), if those variables are
found to be significantly statistically associated with both
the intervention assignment and the outcome examined.
Objective #3: examine the effects of EMPOWER on patient
outcomes in the month following ICU admission
Logistic regression models will regress patient quality of
life or quality of death (depending on whether the patient
survives or dies in the observation period) for EMPOWER
versus the enhanced usual care condition. Logistic regres-
sion analyses will model the effects of EMPOWER on the
odds of patients’ receipt of value-concordant care (i.e., sur-
rogate baseline assessment of patient preferences regard-
ing quality of life versus quantity of life matched with
receipt of intensive life-prolonging procedures/palliative
care). Potential differences in assessment timing between
groups will be adjusted for.
Adverse reactions and events
We anticipate that there may be questions in the inter-
view that some study participants find upsetting. How-
ever, since study items and topics were chosen to reflect
what are likely to be existing concerns, the present study
is not expected to markedly increase participants’ psy-
chological distress above their routine concerns. Topics
covered during the intervention sessions may be emo-
tional, but related distress is expected to be transient
and will be supported by a mental health clinician. In
addition, experienced personnel trained in interviewing
medically ill individuals and their families will administer
all instruments and will be supervised by the study prin-
cipal investigators (PIs). If a participant assigned to the
EMPOWER intervention wishes to stop participating in
the intervention for any reason, we will request that they
inform the researchers, and, if willing and able, inform
the research team of the reason for ceasing participation.
If a participant appears to be at risk for harming him-
self/herself or others during the course of the trial, the
researchers will take immediate action to address this
risk and the participant would become ineligible for con-
tinuing with the study.
Potential adverse events for this project are expected
to be all non-physical in nature. The principal investiga-
tors will report unanticipated and serious adverse events
to the IRB in a timely manner on an ongoing basis. For
the purpose of this study, a serious adverse event is de-
fined as an event that, as a direct result of the study,
causes serious harm to the participant (e.g., that involve-
ment in the study caused the death of or serious injury
to the participant). Adverse events are also reported as
part of the progress reports in the non-competitive and
competitive renewals for the National Institutes of
Health. If at any point during the study period the study
intervention is found to be associated with an undue risk
for harm to subjects, then the trial will be stopped—such
as if the research team determines, in good faith, that
the intervention appears to be causing significant emo-
tional distress or impairment for subjects beyond what
would be expectable or leading to increased risk for
harm to self or others.
All study staff involved in the research are edu-
cated on the protection of human research partici-
pants and the proposed research will comply with
the regulations set forth in 45 CFR Part 46, Protec-
tion of Human Subjects. All personnel involved in
the proposed protocol have been educated regarding
HIPAA regulations and fully understand their re-
sponsibility to safeguard the personal health informa-
tion of every participant involved in the research.
Any participant participating in the study may de-
cline to continue participation and may withdraw
from the study at any time. Any participant who
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expresses a desire for more intensive psychosocial
support for issues such as PTSD or bereavement fol-
lowing the intervention will receive a customized set
of referrals from the study team.
We will collect participants’ medical and mental health
history, details about outside clinicians, and emergency
contact information. Participants will be screened for sui-
cidality with the Columbia Suicide Severity Rating Scale
[15] and in accordance with our screening and manage-
ment guidelines. If research staff identify signs indicating a
significant and acute risk of harm to self or others, such
information will immediately be shared with the PIs of the
study, so that a plan can be enacted for timely and appro-
priate assessment and care, provided by a licensed/ board-
certified mental health provider or local clinicians (e.g.,
emergency rooms near the study participant).
Participant confidentiality will only be broken if infor-
mation gathered during the course of the study indicates
that the participant poses a significant and acute risk of
harm to self or others. Prior to inclusion in the study, par-
ticipants will be informed of this exception. If a participant
deemed to be at acute risk of self-harm or harm to others
cannot be reached by the study team within 3 h (after at
least two telephone call attempts and an email requesting
a call back), the participant’s emergency contact(s) will be
contacted. If an acutely distressed individual who has de-
nied active suicidality or homicidality, but for whom the
study team has significant concern, cannot be reached
within 24 h (after at least two phone call attempts and an
email requesting a call back), the participant’s emergency
contact(s) will be contacted. These details are outlined in
the informed consent for study participation.
Discussion
This trial will evaluate the effects of a mental health inter-
vention conducted in the ICU on surrogate decision-
makers of incapacitated patients. Psychiatric symptoms
of surrogates, participant quality of life and quality of
death, and rates of nonbeneficial, burdensome care
will be examined.
Previous trials led by ICU and palliative care clinicians
have proven inefficacious in improving mental health
outcomes in informal caregivers [5–11]. This trial takes
a different approach by examining a mental health inter-
vention for mental health problems. Additionally, the
EMPOWER intervention will be created and refined
based on the input of a variety of ICU stakeholders, in-
cluding behavioral health clinicians, physicians, and be-
reaved informal caregivers.
Due to the clinical and logistical aspects of the
protocol, the EMPOWER trial will not be blinded.
Also, this pilot RCT has limited statistical power.
Study participants, however, will be recruited from
ICUs across three different hospitals to accelerate re-
cruitment and maximize sample size and diversity.
In addition, these data may be used in support of a
large-scale, adequately powered study.
If efficacious, the EMPOWER intervention has the po-
tential to improve both the mental health outcomes of
informal caregivers and the quality of life at end of life
for incapacitated patients receiving intensive care.
Through stakeholder feedback, an initial open trial, and
an RCT, this pilot study will extensively examine what
may potentially serve as an efficient and flexible inter-
vention for incapacitated patients and their surrogate
decision-makers in the ICU.
Trial status
Enrollment has been completed for both open trial and
stakeholder feedback. Enrollment for the RCT portion of
the EMPOWER trial began in January 2019.
Additional file
Additional file 1: SPIRIT 2013 Checklist: Recommended items to address
in a clinical trial protocol and related documents (DOC 121 kb)
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